Incorporation of Vitamin K Into Uremic Lipoproteins

Vitamin K Deficiency Clinical Trial

Official title: Incorporation of Vitamin K Into Uremic Lipoproteins

Status Completed

Clinical Trial Summary

Chronic kidney disease (CKD) patients have an increased cardiovascular risk with corresponding cardiovascular calcifications. CKD patients exhibit a functional vitamin K deficiency. Calcification can be prevented by vitamin K intake. The aim of this study is to investigate the cause for the vitamin K deficiency beyond a diminished dietary vitamin K uptake.

Clinical Trial Description

This study is a monocentric, 1-armed interventional trial. Participants will be recruited at the University Hospital of the RWTH Aachen.

We will analyse serially collected serum from 10 dialysis patients, after ingestion of a single vitamin K supplement, compared to healthy controls. Lipoprotein fractions will be isolated and the corresponding vitamin K contents will be measured by chromatography.

The vitamin K supplement contains 3 subforms of vitamin K: vitamin K1 (1000µg), menaquinone-4 (1000µg) and menaquinone-7 (200µg). ;

Related Conditions & MeSH terms

• Vitamin K Deficiency

• NCT number: NCT05360342
• Study type: Interventional
• Source: RWTH Aachen University
• Status: Completed
• Phase: N/A
• Start date: March 31, 2020
• Completion date: September 15, 2021